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P
atient 1 was a 39-year-old woman with an unremarkable medical history who devel-
oped acute involuntary right arm and leg movements. Neurologic examination
revealed moderate dysarthria and subcontinuous, choreic movements in her right
limbs, prevailing in the arm, which worsened during postural tasks. She occasionally
had ballistic movements in her right limbs and abnormal dystonic postures. Continuous peri-
buccal and tongue involuntary movements were noted. Moreover, bilateral upper limb ataxia,
gait and trunk ataxia, and brisk right tendon reflexes were found. There was no strength or sen-
sory loss (video 1 at Neurology.org/cp). Brain MRI revealed a tumefactive, T2/fluid-
attenuated inversion recovery (FLAIR) hyperintense, T1 hypointense contrast-enhancing
demyelinating lesion in the left cerebral peduncle, extending to the substantia nigra and
subthalamic nucleus (STN) (fF1 igure, A–C). Multiple hyperintense T2/FLAIR, T1 hypoin-
tense, non-contrast-enhancing demyelinating lesions in the hemispheric and periventricular
deep white matter, brainstem, and cerebellar hemispheres were also found. All serologic tests
were within normal limits. Isoelectric focusing (IEF) revealed 9 CSF oligoclonal bands
(OCBs). A diagnosis of multiple sclerosis (MS) was made and the patient was treated with
high-dose methylprednisolone with improvement of symptoms.
Patient 2 was an 18-year-old man with an unremarkable medical history who developed acute
involuntary left arm and leg movements, dysarthric speech, and mental slowing. Neurologic ex-
amination showed intermittent choreic and occasional choreoathetoid movements associated
with a dystonic posture affecting predominantly the left forearm, hand, or fingers (video 2).
There was no strength, coordination, or sensory loss. Brain MRI revealed a right subthalamic
T2/FLAIR hyperintense, T1 hypointense, contrast-enhancing demyelinating lesion extending
to the homolateral cerebral peduncle (figure, D–F). Multiple T2/FLAIR hyperintense, T1
hypointense non-contrast-enhancing demyelinating lesions involved the left part of the pons-
mesencephalic passage, the homolateral superior cerebellar peduncle, and the corpus callosum.
All serologic and urinary tests, including ceruloplasmin and copper levels, were within normal
limits. IEF revealed 5 CSF OCBs. A diagnosis of MS was made and the patient was treated
with high-dose methylprednisolone. The involuntary movements completely resolved in 6 days.
One month later, the patient developed left facial hemispasm. Brain MRI did not reveal new
lesions. He was newly treated with steroids. Clonazepam and botulinum toxin injection in the
left orbital muscle were also administered, leading to a complete resolution of symptoms.
DISCUSSION
Hyperkinetic movement disorders, in particular chorea and ballism, have been rarely reported
in patients with MS and almost never represent the first clinical manifestation.1 The few cases
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reported in literature had basal ganglia (mainly striatum) demyelinating plaques.1 The occur-
rence of demyelinating lesions in the basal ganglia is explained by the presence of myelinated
fibers within the subcortical gray nuclei.2 Historically, contralateral hemichorea has been
described in relation to subthalamic or thalamic lesions due to various causes.3 In our
patients, the active demyelinating lesions are localized almost exactly in the same regions
as those identified by Lee and Marsden3 as being involved in the development of hemichorea.
These observations, and the clinical improvement following steroid treatment, suggest a direct
relationship between the occurrence of the demyelinating lesions and the onset of involuntary
movements.
Since the STN is somewhat difficult to precisely localize using typical T1- and T2-weighted
imaging, specialist contrast sequences such as susceptibility-weighted imaging have been devel-
oped. These sequences were not performed in our cases; this could have identified the precise
localization of the STN. Thalamic lesions can cause a variety of movement disorders such as
dystonia, tremor, asterixis, pseudochoreoathetosis (a movement disorder resulting from lesions
involving sensory areas in the cortex, spinal cord, dorsal root ganglions, or thalamus), or hemi-
chorea.4 In particular, a small thalamic lesion can cause either typical pseudochoreoathetotic
finger movements, or variable, jerky chorea-like movements, worsened by eye closure.4 Unlike
in pseudochoreoathetosis cases, no sensory deficits were detected in our patients. Choreoa-
thetosis, with different degrees of dystonia, represents the clinical manifestation of peak-dose
levodopa-induced dyskinesia in advanced Parkinson disease (PD).5 Drug-induced dyskinesias
Figure Tesla brain MRI obtained before and after IV gadolinium injection fluid-attenuated
inversion recovery sequences
Two-millimeter slice thickness, 1.23 1.2 mm2 in-plane resolution. T1-weighted postcontrast sequences: 4-mm slice
thickness, 0.85 3 1.06 mm2 in-plane resolution. Patient 1: axial fluid-attenuated inversion recovery brain MRI
shows a tumefactive, hyperintense demyelinating lesion (red arrow) in the left subthalamic region (red circle) in
addition to multiple demyelinating lesions in the hemispheric deep white matter. (A) Coronal fluid-attenuated in-
version recovery brain MRI shows the same signal abnormalities (red arrow) in the left cerebral peduncle, extending
to the substantia nigra and subthalamic nucleus (red circle) with bilateral hyperintense demyelinating lesions in the
periventricular white matter (B). Coronal T1-weighted postcontrast brain MRI of the same anatomic area of image B
demonstrates gadolinium enhancement of the subthalamic lesion (red circle) (C). Patient 2: axial fluid-attenuated
inversion recovery brain MRI reveals a wide hyperintense demyelinating lesion (red arrow) in the right upper sub-
thalamic region (red circle) (D). Coronal fluid-attenuated inversion recovery brain MRI shows hyperintense signal
abnormalities (red arrow) in right cerebral pedunculus, homolateral substantia nigra, subthalamic nucleus (red
circle), and left part of the pons-mesencephalic passage (E). Coronal T1-weighted postcontrast brain MRI demon-
strates gadolinium enhancement of the subthalamic lesion (red circle) (F).
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are possibly associated with STN hypoactivity, as suggested by the occurrence of dyskinesias
in MPTP monkeys and by the occurrence of hemichorea-hemiballism in around 15% of
patients with PD after subthalamotomy or during deep brain stimulation.5–7 In all these
situations, there is a subthalamic hypoactivity, either transient or permanent, caused by
pharmacologic, electrical, or surgical intervention.7
The acute onset of unilateral dyskinesias with semiology ranging from choreoathetosis to
ballism or dystonia, similar to those induced by levodopa, should suggest a functional inhibi-
tion of the STN, with imbalance of motor control operated by the basal ganglia network. Aside
from common cases induced by metabolic or vascular lesions, in young patients, this clinical
picture could suggest an unusual onset of a demyelinating disease.
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